Cebaracetam

Cebaracetam (INNTooltip International Nonproprietary Name; developmental code names CGS-25248; ZY-15119) is an experimental drug of the racetam group described as a nootropic which was never marketed.^[1][2][3]

Cebaracetam

Clinical data
Other names	CGS-25248; ZY-15119
ATC code	None
Legal status
Legal status	US: Unscheduled and not FDA approved
Identifiers
IUPAC name 4-[2-[4-(4-Chlorophenyl)-2-oxopyrrolidin-1-yl]acetyl]piperazin-2-one
CAS Number	113957-09-8 Y
PubChem CID	65919
ChemSpider	59327 Y
UNII	Q25MNP6OC1
ChEMBL	ChEMBL2105942 Y
CompTox Dashboard (EPA)	DTXSID70869580
Chemical and physical data
Formula	C16H18ClN3O3
Molar mass	335.79 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1CN(CC(=O)N1)C(=O)CN2CC(CC2=O)C3=CC=C(C=C3)Cl
InChI InChI=1S/C16H18ClN3O3/c17-13-3-1-11(2-4-13)12-7-15(22)20(8-12)10-16(23)19-6-5-18-14(21)9-19/h1-4,12H,5-10H2,(H,18,21) N Key:QPKMIYNBZGPJAR-UHFFFAOYSA-N N
(verify)

It is a chlorinated acetylpiperazine-substituted analogue of phenylpiracetam and is also a derivative of RGPU-95 (4-chlorophenylpiracetam).^[4] It is the analogue of RGPU-95 in which the terminal amide group has been replaced with a piperazin-2-one moiety.^[4] The mechanism of action of cebaracetam is undefined or unknown.^[1]

The drug was under development by Novartis for the treatment of cognition disorders by the 1990s but development was discontinued in 1995.^[1] It reached phase 2 clinical trials prior to its discontinuation.^[1]